ANNOUNCEMENT NO. 299 4 February 2026 Interim report for the first half of 2025/26 Organic growth despite challenges in the North American market Martin Helbo Behrens, CEO: In the first half of 2025/26 ...
STOCKHOLM, SE / ACCESS Newswire / May 6, 2025 / Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists ...
A presentation will be held via Teams 12/02 at 08.30 am CET, where the CEO presents the report. You can participate by register on the link below: ...
GOTHENBURG, SWEDEN / ACCESS Newswire / February 10, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)XVIVO Perfusion AB (publ) has decided to postpone the publication of its interim report for ...
Period October - December Order intake increased by 5 per cent to MSEK 251 (238), attributable to a major order of MSEK 18 that was received in the third quarter last year in the fourth quarter this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results